| Similar Articles |
|---|
 |
The Motley Fool
November 14, 2007
Brian Lawler |
Neurochem's Crazy Choice Neurochem chooses a risky path for its lead drug candidate, attempting to have its Alzheimer's disease medication marketed as a dietary supplement.   |
The Motley Fool
April 2, 2008
Brian Lawler |
Following the Drugmaker Formerly Known as Neurochem Neurochem would have been set to hear FDA news on its lead drug candidate Kiacta today, if they had not pulled their marketing application earlier this month. |
The Motley Fool
August 27, 2007
Brian Lawler |
Neurochem Down for the Count? With likely two failed compounds - since the FDA rejected Neurochem's amyloidosis compound Kiacta a second time in July -- it's hard to see much value in shares of the company, considering its bare drug pipeline. |
The Motley Fool
June 13, 2007
Brian Lawler |
Neurochem Collects the Data Neurochem hints at the data for its Alzheimer's disease drug candidate. The FDA doesn't like data that is hard to interpret, nor is it a fan of retrospective analyses. Investors, take note. |
The Motley Fool
December 10, 2007
Brian Lawler |
Neurochem's Sure Bet at Failure Investors should add another regulatory date to their biotech calendars, this one regarding Neurochem's lead drug, KIACTA. |
The Motley Fool
June 25, 2007
Brian Lawler |
Neurochem Hems and Haws Neurochem delays the announcement of clinical trial results from its lead drug to treat Alzheimer's disease. Investors would be smart to stay far, far away. |
The Motley Fool
July 18, 2007
Brian Lawler |
More Misery for Neurochem It's hard to find another drug developer that has mishandled its correspondence with investors about its drug candidates as badly as Neurochem has over the past year. |
The Motley Fool
April 23, 2007
Brian Lawler |
Neurochem Sets Low Expectations The specialty drug developer announces an update on plans to release results from a clinical study. Investors, take note. |
The Motley Fool
December 18, 2007
Brian Lawler |
The Final Nail in Neurochem's Coffin The European Medicines Agency announced its refusal to approve Neurochem's lead drug, KIACTA. |
The Motley Fool
February 25, 2008
Brian Lawler |
Supplements Take a Hit The leaders of the company which produces the supplement Enzyte are convicted of deceptive advertising. It was allowed to do this because the FDA takes the opposite approach to supplement producers that it does for pharmaceutical drugmakers. |
The Motley Fool
September 22, 2006
Brian Lawler |
The Truth About Dietary Supplements The real issue here is not about one possibly corrupt supplement company -- it's about customers not knowing that the U.S. supplement industry isn't regulated the way pharmaceutical companies are. |
The Motley Fool
February 8, 2005
Charly Travers |
Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company |
The Motley Fool
April 17, 2007
Brian Lawler |
Neurochem Must Wait The FDA delays a regulatory decision on Neurochem's lead compound. Investors, take note. |
Financial Advisor
July 6, 2010 |
Innovative Alternative Strategies Conference Supplement 2010 The supplement to the Innovative Alternative Strategies Conference is attached. |
The Motley Fool
May 1, 2007
Mike Havrilla |
Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc. |
BusinessWeek
January 8, 2007
Catherine Arnst |
Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure. |
The Motley Fool
May 17, 2005
Rich Smith |
Nutraceutical's Secret Ingredient If it's real-world cash you're after, and steady long-term performance in an investment, Nutraceutical just might make for a healthy supplement to your portfolio. |
The Motley Fool
September 28, 2004
Nathan Parmelee |
Nutraceutical Is Still Very Healthy The company's stock has had a rough few months, but the business still looks strong. |
